Skip to main content
SpringerLink
Log in

BPH and Male Lower Urinary Tract Symptoms

  • Reference work entry
  • First Online:
Geriatric Medicine

  • 359 Accesses

Abstract

Benign prostatic hyperplasia (BPH) is a histological diagnosis indicating an increase in the cell number and size of non-cancerous stromal and glandular tissue that is common in older men. BPH contributes to lower urinary tract symptoms that can be bothersome and that potentially could result in significant bladder outlet obstruction that could require surgery or urgent bladder catheterization. Epidemiological studies have shown that clinically significant BPH is related to obesity and metabolic syndrome. The diagnostic evaluation of BPH requires a history of the onset, duration, and severity of symptoms, and a targeted physical examination. Needed testing includes a urinalysis and perhaps a measure of prostate size or post-void residual. Functional limitations and cognitive impairment have a meaningful impact on the evaluation and management of BPH. Men with moderate to severe BPH symptoms who desire treatment can be managed by behavioral, medication, or surgical treatments. The choice of specific interventions will be influenced by prostate size, but also by the degree of bother, presence of comorbidities, use of concomitant medications, and frailty.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. American Urological Association/Society of Urodynamics Female pelvic medicine and urogenital reconstruction. Diagnosis and treatment of non-neurogenic overactive bladder (OAB) in adults: an AUA/SUFU guideline. 2019.

    Google Scholar 

  2. American Urological Association. 2010 American urological association guideline: management of benign prostatic hyperplasia (BPH). Updated 2014.

    Google Scholar 

  3. Gibson W, Johnson T, Kirschner-Hermanns R, et al. Incontinence in frail elderly persons: report of the 6th international consultation on incontinence. Neurourol Urodyn 2020.

    Google Scholar 

  4. Wei JT, Calhoun E, Jacobsen SJ. Urologic diseases in America project: benign prostatic hyperplasia. J Urol. 2005;173:1256–61.

    Article  PubMed  Google Scholar 

  5. Meikle AW, Bansal A, Murray DK, Stephenson RA, Middleton RG. Heritability of the symptoms of benign prostatic hyperplasia and the roles of age and zonal prostate volumes in twins. Urology. 1999;53:701–6.

    Article  CAS  PubMed  Google Scholar 

  6. D’Ancona C, Haylen B, Oelke M, et al. The International Continence Society (ICS) report on the terminology for adult male lower urinary tract and pelvic floor symptoms and dysfunction. Neurourol Urodyn. 2019;38:433–77.

    Article  PubMed  Google Scholar 

  7. American Urological Association. Guide to surgical management of benign prostatic hyperplasia. 2020.

    Google Scholar 

  8. McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349:2387–98.

    Article  CAS  PubMed  Google Scholar 

  9. Barry MJ, Williford WO, Fowler FJ Jr, Jones KM, Lepor H. Filling and voiding symptoms in the American Urological Association symptom index: the value of their distinction in a veterans affairs randomized trial of medical therapy in men with a clinical diagnosis of benign prostatic hyperplasia. J Urol. 2000;164:1559–64.

    Article  CAS  PubMed  Google Scholar 

  10. Nickel JC, Aaron L, Barkin J, Elterman D, Nachabe M, Zorn KC. Canadian Urological Association guideline on male lower urinary tract symptoms/benign prostatic hyperplasia (MLUTS/BPH): 2018 update. Can Urol Assoc J. 2018;12:303–12.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Kok ET, Schouten BW, Bohnen AM, Groeneveld FP, Thomas S, Bosch JL. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen study. J Urol. 2009;181:710–6.

    Article  PubMed  Google Scholar 

  12. Sandhu JS, Bixler BR, Dahm P, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA guideline amendment 2023. J Urol. 2023. https://doi.org/10.1097/JU.0000000000003698.

  13. Lightner DJ, Gomelsky A, Souter L, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment 2019. J Urol. 2019;202:558.

    Google Scholar 

  14. Barry MJ, Fowler FJ Jr, O'Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992;148:1549–57. discussion 1564

    Article  CAS  PubMed  Google Scholar 

  15. Cockett ATK. The International Consultation on Benign Proastatic Hyperplasia. In: Organization WH, editor. International Consultation on Benign Prostatic Hyperplasia. Paris. 1991.

    Google Scholar 

  16. Chancellor MB, Rivas DA. American Urological Association symptom index for women with voiding symptoms: lack of index specificity for benign prostate hyperplasia. J Urol 1993;150:1706–1708; discussion 1708–1709.

    Google Scholar 

  17. Yap TL, Cromwell DA, Brown C, van der Meulen J, Emberton M. The relationship between objective frequency-volume chart data and the I-PSS in men with lower urinary tract symptoms. Eur Urol. 2007;52:811–8.

    Article  PubMed  Google Scholar 

  18. Brown CT, Yap T, Cromwell DA, et al. Self management for men with lower urinary tract symptoms: randomised controlled trial. BMJ. 2007;334:25.

    Article  PubMed  Google Scholar 

  19. MacDiarmid SA, Peters KM, Chen A, et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clin Proc. 2008;83:1002–10.

    Article  CAS  PubMed  Google Scholar 

  20. Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA. 2006;296:2319–28.

    Article  CAS  PubMed  Google Scholar 

  21. Dubeau CE, Kraus SR, Griebling TL, et al. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial. J Urol. 2014;191:395–404.

    Article  CAS  PubMed  Google Scholar 

  22. Bauer SR, Scherzer R, Suskind AM, et al. Co-occurrence of lower urinary tract symptoms and frailty among community-dwelling older men. J Am Geriatr Soc 2020.

    Google Scholar 

  23. Bauer SR, Jin C, Kamal P, Suskind AM. Association between lower urinary tract symptoms and frailty in older men presenting for urologic care. Urology 2020.

    Google Scholar 

  24. Suskind AM, Jin C, Cooperberg MR, et al. Preoperative frailty is associated with discharge to skilled or assisted living facilities after urologic procedures of varying complexity. Urology. 2016;97:25–32.

    Article  PubMed  Google Scholar 

  25. Desmopressin (Nocdurna and Noctiva) for nocturnal polyuria. Med Lett Drugs Ther. 2019;61:46–8.

    Google Scholar 

  26. Porru D, Jallous H, Cavalli V, Sallusto F, Rovereto B. Prognostic value of a combination of IPSS, flow rate and residual urine volume compared to pressure-flow studies in the preoperative evaluation of symptomatic BPH. Eur Urol. 2002;41:246–9.

    Article  CAS  PubMed  Google Scholar 

  27. Kaplan SA, Roehrborn CG, Abrams P, Chapple CR, Bavendam T, Guan Z. Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review. Int J Clin Pract. 2011;65:487–507.

    Article  CAS  PubMed  Google Scholar 

  28. Burgio KL, Goode PS, Johnson TM, et al. Behavioral versus drug treatment for overactive bladder in men: the male overactive bladder treatment in veterans (MOTIVE) trial. J Am Geriatr Soc. 2011;59:2209–16.

    Google Scholar 

  29. Weiss JP, Blaivas JG, Bliwise DL, et al. The evaluation and treatment of nocturia: a consensus statement. BJU Int. 2011;108:6–21.

    Article  PubMed  Google Scholar 

  30. Yap TL, Cromwell DA, Brown C, Emberton M, van der Meulen J. The reliability of the frequency-volume chart in assessing lower urinary tract symptoms. BJU Int. 2007;100:111–5.

    Article  PubMed  Google Scholar 

  31. Everaert K, Herve F, Bosch R, et al. International continence society consensus on the diagnosis and treatment of nocturia. Neurourol Urodyn. 2019;38:478–98.

    Article  PubMed  Google Scholar 

  32. Burgio KL, Kraus SR, Johnson TM, et al. Effec- tiveness of combined behavioral and drug therapy for overactive bladder symptoms in men: a randomized clinical trial. JAMA Intern Med. 2020;180(3):411–419. https://doi.org/10.1001/jamainternmed.2019.6398.

  33. Johnson TM, 2nd, Vaughan CP, Goode PS, et al. Pilot results from a randomized trial in men comparing alpha-adrenergic antagonist versus behavior and exercise for Nocturia and sleep. Clin Ther 2016.

    Google Scholar 

  34. Davis NJ, Vaughan CP, Johnson TM 2nd, et al. Caffeine intake and its association with urinary incontinence in United States men: results from National Health and nutrition examination surveys 2005–2006 and 2007-2008. J Urol. 2013;189:2170–4.

    Google Scholar 

  35. Burgio KL, Locher JL, Goode PS, et al. Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial. JAMA. 1998;280:1995–2000.

    Article  CAS  PubMed  Google Scholar 

  36. Johnson TM 2nd, Burgio KL, Redden DT, Wright KC, Goode PS. Effects of behavioral and drug therapy on nocturia in older incontinent women. J Am Geriatr Soc. 2005;53:846–50.

    Article  PubMed  Google Scholar 

  37. Burgio KL, Kraus SR, Johnson TM, et al. Effectiveness of combined behavioral and drug therapy for overactive bladder symptoms in men: a randomized clinical trial. JAMA Intern Med. 2020;180(3):411–419. https://doi.org/10.1001/jamainternmed.2019.6398.

  38. Center for Medicare and Medicaid Services/Office of Enterprise Data & Analytics (OEDA). Medicare part D Drugs Vol 2020.

    Google Scholar 

  39. By the American Geriatrics Society Beers Criteria® Update Expert P. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052–2081. https://doi.org/10.1111/jgs.18372. Epub 2023 May 4. PMID: 37139824.

  40. De Nunzio C, Presicce F, Lombardo R, et al. Patient centred care for the medical treatment of lower urinary tract symptoms in patients with benign prostatic obstruction: a key point to improve patients' care - a systematic review. BMC Urol. 2018;18:62.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Cindolo L, Pirozzi L, Fanizza C, et al. Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study. Eur Urol. 2015;68:418–25.

    Article  PubMed  Google Scholar 

  42. Lepor H, Williford WO, Barry MJ, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans affairs cooperative studies benign prostatic hyperplasia study group. N Engl J Med. 1996;335:533–9.

    Article  CAS  PubMed  Google Scholar 

  43. Lee CL, Kuo HC. Tailoring medication for lower urinary tract symptoms in men based on international prostate symptom score voiding to storage ratio. Urology. 2018;120:30–5.

    Article  PubMed  Google Scholar 

  44. McVary K. Medical treatment of benign prostatic hyperplasia. In: O’Leary MP, Givens J, editor. 2020.

    Google Scholar 

  45. VA Pharmacy Benefits Management Services MAP, and VISN Pharmacist Executives. Alpha-blocker combination therapy in PTSD and BPH recommendations for use. In: Semla T, editor. 2012.

    Google Scholar 

  46. Oelke M, Becher K, Castro-Diaz D, et al. Appropriateness of oral drugs for long-term treatment of lower urinary tract symptoms in older persons: results of a systematic literature review and international consensus validation process (LUTS-FORTA 2014). Age Ageing. 2015;44:745–55.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Nabi G, Cody JD, Ellis G, Herbison P, Hay-Smith J. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2006:CD003781.

    Google Scholar 

  48. American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71:2052–2081. https://doi.org/10.1111/jgs.18372.

  49. Coupland CAC, Hill T, Dening T, Morriss R, Moore M, Hippisley-Cox J. Anticholinergic drug exposure and the risk of dementia: a nested case-control study JAMA Intern Med 2019.

    Google Scholar 

  50. Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175:401–7.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Richardson K, Fox C, Maidment I, et al. Anticholinergic drugs and risk of dementia: case-control study. BMJ. 2018;361:k1315.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Welk B, McArthur E. Increased risk of dementia among patients with overactive bladder treated with an anticholinergic medication compared to a beta-3 agonist: a population-based cohort study. BJU Int. 2020; https://doi.org/10.1111/bju.15040. [Epub ahead of print].

  53. Griebling TL, Campbell NL, Mangel J, et al. Effect of mirabegron on cognitive function in elderly patients with overactive bladder: MoCA results from a phase 4 randomized, placebo-controlled study (PILLAR). BMC Geriatr. 2020;20:109.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Gill SS, Mamdani M, Naglie G, et al. A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs. Arch Intern Med. 2005;165:808–13.

    Article  PubMed  Google Scholar 

  55. Landi F, Dell’Aquila G, Collamati A, et al. Anticholinergic drug use and negative outcomes among the frail elderly population living in a nursing home. J Am Med Dir Assoc. 2014;15:825–9.

    Article  PubMed  Google Scholar 

  56. Preston MA. Screening for prostate cancer. UpToDate, September 13, 2023.

    Google Scholar 

  57. Roehrborn CG. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE. BJU Int. 2008;101(Suppl 3):17–21.

    Article  PubMed  Google Scholar 

  58. Merck. Finasteride prescribing information.

    Google Scholar 

  59. Liu L, Zheng S, Han P, Wei Q. Phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis. Urology. 2011;77:123–9.

    Article  PubMed  Google Scholar 

  60. Roehrborn CG, Siami P, Barkin J, et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol. 2008;179:616–21. discussion 621

    Article  CAS  PubMed  Google Scholar 

  61. McVary KT. Surgical treatment of benign prostatic hyperplasia. UpToDate, October 22, 2021.

    Google Scholar 

  62. Suskind AM, Walter LC, Jin C, et al. Impact of frailty on complications in patients undergoing common urological procedures: a study from the American College of Surgeons National Surgical Quality Improvement database. BJU Int. 2016;117:836–42.

    Google Scholar 

  63. Roehrborn CG, Barkin J, Gange SN, et al. Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. Can J Urol. 2017;24:8802–13.

    Google Scholar 

  64. Johnson TM 2nd, Burrows PK, Kusek JW, et al. The effect of doxazosin, finasteride and combination therapy on nocturia in men with benign prostatic hyperplasia. J Urol. 2007;178:2045–50. discussion 2050-2041

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Birmingham/Atlanta VA GRECC, Emory University General Internal Medicine and Family and Preventive Medicine, Atlanta, USA

    Theodore M. Johnson II

  2. Birmingham/Atlanta VA GRECC, Emory University Geriatrics and Gerontology, Atlanta, USA

    Anna Mirk

Authors
  1. Theodore M. Johnson II
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anna Mirk
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Theodore M. Johnson II .

Editor information

Editors and Affiliations

  1. California Association of Long Term Care Medicine, Newbury Park, CA, USA

    Michael R. Wasserman

  2. Betty Irene Moore School of Nursing, University of California, Davis, Sacramento, CA, USA

    Debra Bakerjian

  3. Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA

    Sunny Linnebur

  4. Division of Geriatrics, SUNY Upstate Medical University, Syracuse, NY, USA

    Sharon Brangman

  5. Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy

    Matteo Cesari

  6. Section of Geriatric Medicine, Division of Internal Medicine, Department of Medicine, Cedars-Sinai, Beverly Hills, CA, USA

    Sonja Rosen

Section Editor information

  1. Department of Clinical Pharmacy, University of Colorado School of Pharmacy and Pharmaceutical Sciences, Aurora, Colorado, USA

    Sunny Linnebur PharmD

Rights and permissions

Reprints and permissions

Copyright information

© 2024 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Johnson, T.M., Mirk, A. (2024). BPH and Male Lower Urinary Tract Symptoms. In: Wasserman, M.R., Bakerjian, D., Linnebur, S., Brangman, S., Cesari, M., Rosen, S. (eds) Geriatric Medicine. Springer, Cham. https://doi.org/10.1007/978-3-030-74720-6_114

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-74720-6_114

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-74719-0

  • Online ISBN: 978-3-030-74720-6

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation